0001735276-24-000010.txt : 20240220 0001735276-24-000010.hdr.sgml : 20240220 20240220160912 ACCESSION NUMBER: 0001735276-24-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garg Pushkal CENTRAL INDEX KEY: 0001829252 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 24653323 MAIL ADDRESS: STREET 1: C/O SQZ BIOTECHNOLOGIES COMPANY STREET 2: 200 ARSENAL YARDS BOULEVARD, SUITE 210 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-02-15 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001829252 Garg Pushkal 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 0 1 0 0 CMO & EVP Dev & Med Affairs 0 Common Stock 2024-02-15 4 A 0 4295 0.0 A 8640 D Common Stock 2024-02-16 4 S 0 480 147.5 D 8160 D Common Stock 2024-02-16 4 S 0 672 148.24 D 7488 D Common Stock 2024-02-16 4 S 0 156 149.03 D 7332 D Common Stock 431 I by Managed Account Common Stock 250 I by Trust On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. By: Stephen Hall, Attorney-in-Fact For: Pushkal Garg 2024-02-20